NYSE:JNJ

Johnson & Johnson (JNJ) Stock Forecast, Price & News

$160.26

+1.74 (+1.10%)

(As of 06/8/2023 ET)

Compare

Today's Range: $157.82
▼
$160.42
50-Day Range: $154.35
▼
$166.11
52-Week Range: $150.11
▼
$183.35

Volume: 5.74 million shs
Average Volume: 7.60 million shs
Market Capitalization: $416.47 billion

P/E Ratio: 33.53
Dividend Yield: 2.97%
Price Target: $171.57

Johnson & Johnson MarketRank™ Forecast

Analyst Rating: Hold
2.46 Rating Score
Upside/Downside: 7.1% Upside
$171.57 Price Target
Short Interest: Healthy
0.52% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.98
Upright™ Environmental Score
News Sentiment: 0.28
Based on 17 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 3.28%
From $10.66 to $11.01 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

198th out of 986 stocks

Pharmaceutical Preparations Industry

88th out of 473 stocks

2.2

Analyst's Opinion

Consensus Rating
Johnson & Johnson has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $171.57, Johnson & Johnson has a forecasted upside of 7.1% from its current price of $160.26.
Amount of Analyst Coverage
Johnson & Johnson has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.52% of the float of Johnson & Johnson has been sold short.
Short Interest Ratio / Days to Cover
Johnson & Johnson has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Johnson & Johnson has recently increased by 5.81%, indicating that investor sentiment is decreasing significantly.

3.3

Dividend Strength

Dividend Yield
Johnson & Johnson pays a meaningful dividend of 3.01%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Johnson & Johnson has been increasing its dividend for 62 years.
Dividend Coverage
The dividend payout ratio of Johnson & Johnson is 99.58%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 43.23% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Johnson & Johnson has received a 52.68% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ustekinumab", "Clinical research services for physical health", "Rivaroxaban", "Daratumumab", "Ibrutinib", and "HIV medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Johnson & Johnson is -1.98.

1.3

News and Social Media Coverage

News Sentiment
Johnson & Johnson has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for Johnson & Johnson this week, compared to 22 articles on an average week.
Search Interest
Only 193 people have searched for JNJ on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
Only 59 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Johnson & Johnson insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.20% of the stock of Johnson & Johnson is held by insiders.
Percentage Held by Institutions
67.94% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Johnson & Johnson are expected to grow by 3.28% in the coming year, from $10.66 to $11.01 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Johnson & Johnson is 33.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.18.
Price to Earnings Ratio vs. Sector
The P/E ratio of Johnson & Johnson is 33.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 127.67.
Price to Earnings Growth Ratio
Johnson & Johnson has a PEG Ratio of 2.70. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Johnson & Johnson has a P/B Ratio of 5.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.

Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Stock News Headlines

June 1, 2023 | marketbeat.com

20 Best Healthcare Dividend Stocks to Invest in (JNJ)

Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.

May 31, 2023 | marketbeat.com

The How and Why of Investing in Biotech Stocks (JNJ)

One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccines

June 8, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 23, 2023 | marketbeat.com

Will Dividends Take Center Stage In The Second Half Of 2023? (JNJ)

The NYSE Composite's sideways trade since early 2021 could be a warning sign, suggesting that a shift toward dividend strategies may be prudent.

May 15, 2023 | marketbeat.com

Is Novavax Finally Turning Things Around? (JNJ)

Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea

May 15, 2023 | marketbeat.com

UnitedHealth Group is an AI Stock That Isn't Beating Expectations (JNJ)

Although it's a pioneer in AI, UnitedHealth Group is not enjoying the halo effect on AI stocks, but with more clarity on future growth that should change

May 12, 2023 | marketbeat.com

3 Recession-Proof Stocks With Nice Dividends (JNJ)

Certain sectors like consumer staples and health care tend to outperform during economic turbulence. These three stocks are good names to own for the bad times.

May 10, 2023 | marketbeat.com

5 Best Healthcare Sector ETFs (JNJ)

What do you need to know about investing in healthcare ETFs? Learn more about both healthcare and ETFs with MarketBeat.

June 8, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 9, 2023 | marketbeat.com

J&J Kenvue Spinoff Aims To Give Investors A Healthy Return (JNJ)

Johnson & Johnson spinoff Kenvue had the biggest IPO since 2021, raising $3.8 billion. Kenvue's brands include Band-Aid, Tylenol, Neutrogena and Listerine.

May 8, 2023 | marketbeat.com

June 8, 2023 | finance.yahoo.com

Investors in Johnson & Johnson (NYSE:JNJ) have seen favorable returns of 48% over the past five years

June 7, 2023 | msn.com

Mizuho Maintains Johnson & Johnson (JNJ) Prior Recommendation

June 7, 2023 | markets.businessinsider.com

Johnson & Johnson (JNJ) Gets a Buy from SVB Securities

June 6, 2023 | finance.yahoo.com

Tylenol Maker Kenvue Goes From Sure Bet to Question Mark After Year’s Biggest IPO

June 6, 2023 | markets.businessinsider.com

Alkermes Raises FY23 Guidance With Final Award In Johnson & Johnson Unit Arbitration

June 6, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sight Sciences (SGHT), Johnson & Johnson (JNJ) and Ultragenyx Pharmaceutical (RARE)

June 6, 2023 | msn.com

Alkermes lifts outlook after arbitration payment from Johnson & Johnson

June 6, 2023 | finance.yahoo.com

20 Most Respected Professions in the World

June 4, 2023 | finance.yahoo.com

2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip

June 4, 2023 | finance.yahoo.com

1 Ultra-Elite Dividend Stock to Buy Hand Over Fist in June

June 3, 2023 | finance.yahoo.com

Two Dow Stocks to Buy in June and Hold for the Next Decade

June 3, 2023 | finance.yahoo.com

With 65% ownership, Johnson & Johnson (NYSE:JNJ) boasts of strong institutional backing

June 2, 2023 | finance.yahoo.com

LAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection

June 2, 2023 | msn.com

JNJ Whistleblower Case Dismissed Over Confidentiality Breach

June 2, 2023 | msn.com

Whistleblower lawsuit against Johnson & Johnson dismissed over leaked trade secrets

June 1, 2023 | finance.yahoo.com

UPDATE 1-J&J secures dismissal of whistleblower case over misuse of confidential info

See More Headlines

JNJ Price History

30 days | 90 days | 365 days | Advanced Chart

JNJ Company Calendar

Last Earnings: 4/18/2023
Ex-Dividend for 6/6 Dividend: 5/22/2023
Dividend Payable: 6/06/2023
Today: 6/08/2023
Next Earnings (Confirmed): 7/20/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:JNJ
CUSIP: 47816010
CIK: 200406
Web: www.jnj.com
Phone: (732) 524-0400
Fax: 732-214-0332
Employees: 155,800
Year Founded: 1886

Price Target and Rating

Average Stock Price Forecast: $171.57
High Stock Price Forecast: $215.00
Low Stock Price Forecast: $52.00
Forecasted Upside/Downside: +7.1%
Consensus Rating: Hold
Rating Score (0-4): 2.46
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): $4.78
Trailing P/E Ratio: 33.53
Forward P/E Ratio: 15.03
P/E Growth: 2.7
Net Income: $17.94 billion
Net Margins: 13.22%
Pretax Margin: 15.71%
Return on Equity: 36.13%
Return on Assets: 14.66%

Debt

Debt-to-Equity Ratio: 0.49
Current Ratio: 1.07
Quick Ratio: 0.85

Sales & Book Value

Annual Sales: $94.94 billion
Price / Sales: 4.39
Cash Flow: $13.18 per share
Price / Cash Flow: 12.16
Book Value: $29.39 per share
Price / Book: 5.45

Miscellaneous

Outstanding Shares: 2,598,730,000
Free Float: 2,593,537,000
Market Cap: $416.47 billion
Optionable: Optionable
Beta: 0.54

Social Links

Key Executives

Joaquin Duato
Chairman & Chief Executive Officer

Joseph J. Wolk
Chief Financial Officer & Executive Vice President

Matthew Stuckley
Senior Finance Director

James D. Swanson
Global Chief Information Officer & Executive VP

Joanne Waldstreicher
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JNJ Stock - Frequently Asked Questions

Should I buy or sell Johnson & Johnson stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" JNJ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNJ, but not buy additional shares or sell existing shares.
View JNJ analyst ratings or view top-rated stocks.
What is Johnson & Johnson's stock price forecast for 2023?: 13 Wall Street analysts have issued twelve-month target prices for Johnson & Johnson's stock. Their JNJ share price forecasts range from $52.00 to $215.00. On average, they predict the company's stock price to reach $171.57 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for JNJ or view top-rated stocks among Wall Street analysts.
How have JNJ shares performed in 2023?: Johnson & Johnson's stock was trading at $176.65 at the start of the year. Since then, JNJ shares have decreased by 9.3% and is now trading at $160.26.
View the best growth stocks for 2023 here.
Are investors shorting Johnson & Johnson?: Johnson & Johnson saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 12,740,000 shares, a drop of 9.5% from the April 15th total of 14,070,000 shares. Based on an average daily volume of 7,830,000 shares, the short-interest ratio is presently 1.6 days. Currently, 0.5% of the shares of the stock are short sold.
View Johnson & Johnson's Short Interest.
When is Johnson & Johnson's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 20th 2023.
View our JNJ earnings forecast.
How can I listen to Johnson & Johnson's earnings call?: Johnson & Johnson will be holding an earnings conference call on Thursday, July 20th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13739164".
How were Johnson & Johnson's earnings last quarter?: Johnson & Johnson (NYSE:JNJ) released its quarterly earnings data on Tuesday, April, 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a trailing twelve-month return on equity of 36.13% and a net margin of 13.22%. The company's quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.67 EPS.
Read the conference call transcript.
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?: Johnson & Johnson announced a quarterly dividend on Tuesday, April 18th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share on Tuesday, June 6th. This represents a $4.76 annualized dividend and a yield of 2.97%. The ex-dividend date is Monday, May 22nd. This is a boost from the stock's previous quarterly dividend of $1.13.
Read our dividend analysis for JNJ.
What ETFs hold Johnson & Johnson's stock?: ETFs with the largest weight of Johnson & Johnson (NYSE:JNJ) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Health Care Select Sector SPDR Fund (XLV), iShares U.S. Healthcare ETF (IYH), Optimize AI Smart Sentiment Event-Driven ETF (OAIE), VanEck Pharmaceutical ETF (PPH), Fidelity MSCI Health Care Index ETF (FHLC), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Vanguard Health Care ETF (VHT).
Is Johnson & Johnson a good dividend stock?: Johnson & Johnson (NYSE:JNJ) pays an annual dividend of $4.76 per share and currently has a dividend yield of 3.01%. The company has been increasing its dividend for 62 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 99.58%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, JNJ will have a dividend payout ratio of 43.23% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for JNJ.

How will Johnson & Johnson's stock buyback program work?: Johnson & Johnson announced that its Board of Directors has authorized a share buyback plan on Wednesday, September 14th 2022, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.
What guidance has Johnson & Johnson issued on next quarter's earnings?: Johnson & Johnson updated its FY 2023 earnings guidance on Wednesday, April, 19th. The company provided EPS guidance of $10.60-$10.70 for the period, compared to the consensus EPS estimate of $10.51. The company issued revenue guidance of $97.90 billion-$98.90 billion, compared to the consensus revenue estimate of $97.71 billion.
What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?: 2,535 employees have rated Johnson & Johnson Chief Executive Officer Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among the company's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Johnson & Johnson own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), Procter & Gamble (PG) and AbbVie (ABBV).
What is Johnson & Johnson's stock symbol?: Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
Who are Johnson & Johnson's major shareholders?: Johnson & Johnson's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.75%), State Street Corp (5.40%), Geode Capital Management LLC (1.87%), Price T Rowe Associates Inc. MD (1.03%), Wellington Management Group LLP (0.98%) and FMR LLC (0.68%). Insiders that own company stock include Ashley Mcevoy, James D Swanson, Jennifer L Taubert, Joseph J Wolk, Kathryn E Wengel, Michael E Sneed, Peter Fasolo, Robert J Decker, Thibaut Mongon and William Hait.
View institutional ownership trends.
How do I buy shares of Johnson & Johnson?: Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Johnson & Johnson's stock price today?: One share of JNJ stock can currently be purchased for approximately $160.26.
How much money does Johnson & Johnson make?: Johnson & Johnson (NYSE:JNJ) has a market capitalization of $416.47 billion and generates $94.94 billion in revenue each year. The company earns $17.94 billion in net income (profit) each year or $4.78 on an earnings per share basis.
How many employees does Johnson & Johnson have?: The company employs 155,800 workers across the globe.
Does Johnson & Johnson have any subsidiaries?: The following companies are subsidiares of Johnson & Johnson: 3Dintegrated ApS, ALZA Corporation, AMO (Hangzhou) Co. Ltd., AMO (Shanghai) Medical Devices Trading Co. Ltd Beijing Branch, AMO (Shanghai) Medical Devices Trading Co. Ltd Guangzhou Branch, AMO (Shanghai) Medical Devices Trading Co. Ltd., AMO ASIA LIMITED, AMO Asia Limited (Korea Branch), AMO Asia Limited Taiwan Branch (Hong Kong), AMO Australia Pty Limited, AMO Australia Pty Limited (New Zealand Branch), AMO Canada Company, AMO Denmark ApS, AMO Development LLC, AMO France, AMO Germany GmbH, AMO Groningen B.V., AMO International Holdings Unlimited Company, AMO Ireland, AMO Ireland Ireland Branch, AMO Italy SRL, AMO Japan K.K., AMO Manufacturing USA LLC, AMO Netherlands BV, AMO Nominee Holdings LLC, AMO Norway AS, AMO Puerto Rico Manufacturing Inc., AMO Sales and Service Inc., AMO Singapore Pte. Ltd., AMO Spain Holdings LLC, AMO Switzerland GmbH, AMO U.K. Holdings LLC, AMO United Kingdom Ltd., AMO Uppsala AB, AUB Holdings LLC, Abott Medical Optics, Acclarent Inc., Actelion Ltd, Actelion Pharmaceuticals, Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd., Actelion Pharmaceuticals US Inc., Actelion Treasury Unlimited Company, Akros Medical Inc., Albany Street LLC, Alios BioPharma, Alza Land Management Inc., Anakuria Therapeutics Inc., Animas Diabetes Care LLC, Animas LLC, Animas Technologies LLC, AorTx Inc., Apsis, Aragon Pharmaceuticals, Aragon Pharmaceuticals Inc., Asia Pacific Holdings LLC, Atrionix Inc., Auris Health, Auris Health Inc., Backsvalan 2 Aktiebolag, Backsvalan 6 Handelsbolag, Beijing Dabao Cosmetics Co. Ltd., BeneVir BioPharm Inc., Berna Rhein B.V., BioMedical Enterprises Inc., Biosense Webster (Israel) Ltd., Biosense Webster Inc., Branch of Johnson & Johnson LLC (RU) in Kazakhstan, C Consumer Products Denmark ApS, CSATS Inc., Calibra Medical LLC, Campus-Foyer Apotheke GmbH, Carlo Erba OTC S.r.l., Centocor Biologics LLC, Centocor Research & Development Inc., Cerenovus Inc., ChromaGenics B.V., Ci:Labo Customer Marketing Co. Ltd., Ci:Labo USA Inc., Ci:z Holdings, Ci:z. Labo Co. Ltd., Cilag AG, Cilag GmbH International, Cilag Holding AG, Cilag Holding Treasury Unlimited Company, Cilag-Biotech S.L., CoTherix Inc., Coherex Medical Inc., ColBar LifeScience Ltd., Company Store.com Inc., Conor MedSystems, Cordis International Corporation, Cordis de Mexico S.A. de C.V., Corimmun GmbH, DePuy Hellas SA, DePuy International Limited, DePuy Ireland Unlimited Company, DePuy Mexico S.A. de C.V., DePuy Mitek LLC, DePuy Orthopaedics Inc., DePuy Products Inc., DePuy Spine LLC, DePuy Synthes Gorgan Limited, DePuy Synthes Inc., DePuy Synthes Institute LLC, DePuy Synthes Leto SARL, DePuy Synthes Products Inc., DePuy Synthes Sales Inc., Debs-Vogue Corporation (Proprietary) Limited, Dutch Holding LLC, ECL7 LLC, EES Holdings de Mexico S. de R.L. de C.V., EES S.A. de C.V., EIT Emerging Implant Technologies GmbH, Ethicon Endo-Surgery (Europe) GmbH, Ethicon Endo-Surgery Inc., Ethicon Endo-Surgery LLC, Ethicon Inc., Ethicon LLC, Ethicon PR Holdings Unlimited Company, Ethicon Sarl, Ethicon US LLC, Ethicon Women's Health & Urology Sarl, Ethnor (Proprietary) Limited, Ethnor Farmaceutica S.A., Ethnor del Istmo S.A., FMS Future Medical System SA, Finsbury (Development) Limited, Finsbury (Instruments) Limited, Finsbury Medical Limited, Finsbury Orthopaedics International Limited, Finsbury Orthopaedics Limited, GH Biotech Holdings Limited, GMED Healthcare BV, GMED Healthcare BV (Branch), Global Investment Participation B.V., Guangzhou Bioseal Biotech Co. Ltd., Hansen Medical Deutschland GmbH, Hansen Medical Inc., Hansen Medical International Inc., Hansen Medical UK Limited, Healthcare Services (Shanghai) Ltd., Hickory Merger Sub Inc., I.D. Acquisition Corp., Innomedic Gesellschaft für innovative Medizintechnik und Informatik mbH, Innovative Surgical Solutions LLC, J & J Company West Africa Limited, J&J Pension Trustees Limited, J-C Health Care Ltd., J.C. General Services BV, JJ Surgical Vision Spain S.L., JJC Acquisition Company B.V., JJHC LLC, JJSV Belgium BV, JJSV Manufacturing Malaysia SDN. BHD., JJSV Norden AB, JJSV Produtos Oticos Ltda., JNJ Global Business Services s.r.o., JNJ Holding EMEA B.V., JNJ International Investment LLC, JOM Pharmaceutical Services Inc., Janssen Alzheimer Immunotherapy (Holding) Limited, Janssen BioPharma LLC, Janssen Biologics (Ireland) Limited, Janssen Biologics B.V., Janssen Biotech Inc., Janssen Cilag C.A., Janssen Cilag Farmaceutica S.A., Janssen Cilag S.p.A., Janssen Cilag SPA, Janssen Development Finance Unlimited Company, Janssen Diagnostics LLC, Janssen Egypt LLC, Janssen Farmaceutica Portugal Lda, Janssen Global Services LLC, Janssen Holding GmbH, Janssen Inc., Janssen Irish Finance Unlimited Company, Janssen Korea Ltd., Janssen Oncology Inc., Janssen Ortho LLC, Janssen Pharmaceutica (Proprietary) Limited, Janssen Pharmaceutica NV, Janssen Pharmaceutica S.A., Janssen Pharmaceutical K.K., Janssen Pharmaceutical Sciences Unlimited Company, Janssen Pharmaceutical Unlimited Company, Janssen Pharmaceuticals Inc., Janssen Pharmaceuticals Inc. Japan Branch, Janssen Products LP, Janssen R&D Ireland Unlimited Company, Janssen Research & Development LLC, Janssen Sciences Ireland Unlimited Company, Janssen Scientific Affairs LLC, Janssen Supply Group LLC, Janssen Vaccines & Prevention B.V., Janssen Vaccines Branch of Cilag GmbH International, Janssen Vaccines Corp., Janssen-Cilag, Janssen-Cilag (New Zealand) Limited, Janssen-Cilag A/S, Janssen-Cilag AG, Janssen-Cilag AS, Janssen-Cilag Aktiebolag, Janssen-Cilag B.V., Janssen-Cilag Farmaceutica Lda., Janssen-Cilag Farmaceutica Ltda., Janssen-Cilag GmbH, Janssen-Cilag International NV, Janssen-Cilag Kft., Janssen-Cilag Kft. Branch Office, Janssen-Cilag Limited, Janssen-Cilag Manufacturing LLC, Janssen-Cilag NV, Janssen-Cilag OY, Janssen-Cilag Pharma GmbH, Janssen-Cilag Pharmaceutical S.A.C.I., Janssen-Cilag Polska Sp. z o.o., Janssen-Cilag Pty Ltd, Janssen-Cilag Pty Ltd (Branch), Janssen-Cilag S.A., Janssen-Cilag S.A., Janssen-Cilag S.A. de C.V., Janssen-Cilag de Mexico S. de R.L. de C.V., Janssen-Cilag s.r.o., Janssen-Pharma S.L., Jevco Holding Inc., Johnson & Johnson, Johnson & Johnson (Angola) Limitada, Johnson & Johnson (China) Investment Ltd., Johnson & Johnson (China) Investment Ltd. Beijing Branch, Johnson & Johnson (Egypt) S.A.E., Johnson & Johnson (Hong Kong) Limited, Johnson & Johnson (Ireland) Limited, Johnson & Johnson (Jamaica) Limited, Johnson & Johnson (Kenya) Limited, Johnson & Johnson (Middle East) Inc., Johnson & Johnson (Middle East) Inc. (DHCC Branch), Johnson & Johnson (Middle East) Inc. (JAFZA Branch), Johnson & Johnson (Middle East) Inc. Service Center (DAFZA Branch), Johnson & Johnson (Mozambique) Limitada, Johnson & Johnson (Namibia) (Proprietary) Limited, Johnson & Johnson (New Zealand) Limited, Johnson & Johnson (Philippines) Inc., Johnson & Johnson (Private) Limited, Johnson & Johnson (Thailand) Ltd., Johnson & Johnson (Trinidad) Limited, Johnson & Johnson (Vietnam) Co. Ltd, Johnson & Johnson - Societa' Per Azioni, Johnson & Johnson AB, Johnson & Johnson AB Eesti filiaal (Branch), Johnson & Johnson AG, Johnson & Johnson AG (Zuchwil Branch), Johnson & Johnson Belgium Finance Company BV, Johnson & Johnson Bulgaria EOOD, Johnson & Johnson China Ltd., Johnson & Johnson Consumer (Hong Kong) Limited, Johnson & Johnson Consumer (Thailand) Limited, Johnson & Johnson Consumer B.V., Johnson & Johnson Consumer Health Care Switzerland Branch of Janssen-Cilag AG, Johnson & Johnson Consumer Holdings France, Johnson & Johnson Consumer Inc., Johnson & Johnson Consumer Inc. (Dominican Republic Branch), Johnson & Johnson Consumer NV, Johnson & Johnson Consumer Saudi Arabia Limited, Johnson & Johnson Consumer Services EAME Ltd., Johnson & Johnson Del Paraguay S.A., Johnson & Johnson Dominicana S.A.S., Johnson & Johnson Enterprise Innovation Inc., Johnson & Johnson European Treasury Unlimited Company, Johnson & Johnson Finance Corporation, Johnson & Johnson Finance Limited, Johnson & Johnson Financial Services GmbH, Johnson & Johnson Financial Services GmbH (Branch Office), Johnson & Johnson Gateway LLC, Johnson & Johnson Gesellschaft m.b.H., Johnson & Johnson GmbH, Johnson & Johnson Guatemala S.A., Johnson & Johnson Health Care Systems Inc., Johnson & Johnson Health and Wellness Solutions Inc., Johnson & Johnson Hellas Commercial and Industrial S.A., Johnson & Johnson Hellas Consumer Products Commercial Societe Anonyme, Johnson & Johnson Hemisferica S.A., Johnson & Johnson Holding GmbH, Johnson & Johnson Inc., Johnson & Johnson Industrial Ltda., Johnson & Johnson Innovation - JJDC Inc., Johnson & Johnson Innovation LLC, Johnson & Johnson Innovation Limited, Johnson & Johnson International, Johnson & Johnson International (Belgian Branch) (European Logistics Center), Johnson & Johnson International (Singapore) Pte. Ltd., Johnson & Johnson International (Singapore) Pte. Ltd. (Branch), Johnson & Johnson International Financial Services Unlimited Company, Johnson & Johnson K.K., Johnson & Johnson Kft., Johnson & Johnson Korea Ltd., Johnson & Johnson Korea Selling & Distribution LLC, Johnson & Johnson LLC, Johnson & Johnson Lda, Johnson & Johnson Limited, Johnson & Johnson Limited (Sri Lanka Branch), Johnson & Johnson Luxembourg Finance Company Sarl, Johnson & Johnson Management Limited, Johnson & Johnson Medical (China) Ltd., Johnson & Johnson Medical (Proprietary) Ltd, Johnson & Johnson Medical (Shanghai) Ltd., Johnson & Johnson Medical (Shanghai) Ltd. Beijing Branch, Johnson & Johnson Medical (Suzhou) Ltd., Johnson & Johnson Medical B.V., Johnson & Johnson Medical Devices & Diagnostics Group - Latin America L.L.C., Johnson & Johnson Medical GmbH, Johnson & Johnson Medical Korea Ltd., Johnson & Johnson Medical Limited, Johnson & Johnson Medical Mexico S.A. de C.V., Johnson & Johnson Medical NV, Johnson & Johnson Medical Products GmbH, Johnson & Johnson Medical Pty Ltd, Johnson & Johnson Medical S.A., Johnson & Johnson Medical S.C.S., Johnson & Johnson Medical S.p.A., Johnson & Johnson Medical SAS, Johnson & Johnson Medical Saudi Arabia Limited, Johnson & Johnson Medical Taiwan Ltd., Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi, Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi (Ankara Branch), Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi (Izmir Branch), Johnson & Johnson Middle East - Scientific Office, Johnson & Johnson Middle East FZ - LLC (Lebanese Branch), Johnson & Johnson Middle East FZ-LLC, Johnson & Johnson Middle East FZ-LLC (Ghana Branch), Johnson & Johnson Middle East FZ-LLC (Kenya Branch), Johnson & Johnson Middle East FZ-LLC Branch (TSO) (Saudi Arabia Branch), Johnson & Johnson Morocco Societe Anonyme, Johnson & Johnson NCB (Belgian Branch), Johnson & Johnson Nordic AB, Johnson & Johnson Pacific Pty Limited, Johnson & Johnson Pakistan (Private) Limited, Johnson & Johnson Panama S.A., Johnson & Johnson Personal Care (Chile) S.A., Johnson & Johnson Poland Sp. z o.o., Johnson & Johnson Poland sp. z o.o. oddzial w Warszawie "Consumer", Johnson & Johnson Private Limited, Johnson & Johnson Pte. Ltd., Johnson & Johnson Pte. Ltd. Korea Branch, Johnson & Johnson Pty. Limited, Johnson & Johnson Romania S.R.L., Johnson & Johnson S.A., Johnson & Johnson S.A. de C.V., Johnson & Johnson S.E. Inc., Johnson & Johnson S.E. d.o.o., Johnson & Johnson SDN. BHD., Johnson & Johnson Sante Beaute France, Johnson & Johnson Services Inc., Johnson & Johnson Surgical Vision Inc., Johnson & Johnson Surgical Vision India Private Limited, Johnson & Johnson Taiwan Ltd., Johnson & Johnson UK Treasury Company Limited, Johnson & Johnson Ukraine LLC, Johnson & Johnson Urban Renewal Associates, Johnson & Johnson Vision Care (Shanghai) Ltd., Johnson & Johnson Vision Care Inc., Johnson & Johnson Vision Care Ireland Unlimited Company, Johnson & Johnson d.o.o., Johnson & Johnson de Argentina S.A.C. e. I., Johnson & Johnson de Chile Limitada, Johnson & Johnson de Chile S.A., Johnson & Johnson de Colombia S.A., Johnson & Johnson de Mexico S.A. de C.V., Johnson & Johnson de Uruguay S.A., Johnson & Johnson de Venezuela S.A., Johnson & Johnson del Ecuador S.A., Johnson & Johnson del Peru S.A., Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda., Johnson & Johnson for Export and Import LLC, Johnson & Johnson s.r.o., Johnson Y Johnson de Costa Rica S.A., Johnson and Johnson (Proprietary) Limited, Johnson and Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi, LTL Management LLC, La Concha Land Investment Corporation, Latam International Investment Company Unlimited Company, Legal Entity Name, MDS Co. Ltd., McNEIL MMP LLC, McNeil AB, McNeil Consumer Pharmaceuticals Co., McNeil Denmark ApS, McNeil Healthcare (Ireland) Limited, McNeil Healthcare (UK) Limited, McNeil Healthcare LLC, McNeil Iberica S.L.U., McNeil LA LLC, McNeil Nutritionals LLC, McNeil Panama LLC, McNeil Products Limited, McNeil Sweden AB, Medical Device Business Services Inc., Medical Devices & Diagnostics Global Services LLC, Medical Devices International LLC, Medos International Sarl, Medos International Sàrl succursale de Neuchâtel (Branch), Medos Sarl, MegaDyne Medical Products Inc., Menlo Care De Mexico S.A. de C.V., Mentor B.V., Mentor Deutschland GmbH, Mentor Medical Systems B.V., Mentor Partnership Holding Company I LLC, Mentor Texas GP LLC, Mentor Texas L.P., Mentor Worldwide LLC, Micrus Endovascular LLC, Middlesex Assurance Company Limited, Momenta Ireland Limited, Momenta Pharmaceuticals, Momenta Pharmaceuticals Inc., NeoStrata Company Inc., NeoStrata UG (haftungsbeschränkt), Netherlands Holding Company, NeuWave Medical Inc., Neuravi Limited, Novira Therapeutics, Novira Therapeutics LLC, NuVera Medical Inc., OBTECH Medical Sarl, OGX Beauty Limited, OMJ Holding GmbH, OMJ Ireland Unlimited Company, OMJ Pharmaceuticals Inc., Obtech Medical Mexico S.A. de C.V., Omrix Biopharmaceuticals Inc., Omrix Biopharmaceuticals Ltd., Omrix Biopharmaceuticals NV, Ortho Biologics LLC, Ortho Biotech Holding LLC, Ortho-McNeil Pharmaceutical LLC, Orthospin Ltd., Orthotaxy, PT Integrated Healthcare Indonesia, PT. Johnson & Johnson Indonesia, Patriot Pharmaceuticals LLC, Peninsula Pharmaceuticals LLC, Pharmadirect Ltd., Pharmedica Laboratories (Proprietary) Limited, Princeton Laboratories Inc., Productos de Cuidado Personal y de La Salud de Bolivia S.R.L., Proleader S.A., Pulsar Vascular Inc., Regency Urban Renewal Associates, RespiVert Ltd., RoC International, Royalty A&M LLC, Rutan Realty LLC, SYNTHES Medical Immobilien GmbH, Scios LLC, Sedona Singapore International Pte. Ltd., Sedona Thai International Co. Ltd., Serhum S.A. de C.V., Shanghai Elsker For Mother & Baby Co. Ltd, Shanghai Elsker Mother & Baby Co. Ltd Minghang Branch, Shanghai Johnson & Johnson Ltd., Shanghai Johnson & Johnson Pharmaceuticals Ltd., Sightbox LLC, Sodiac ESV, Spectrum Vision Limited Liability Company, Spectrum Vision Limited Liability Partnership, SterilMed, SterilMed Inc., Surgical Process Institute Deutschland GmbH, Synthes Costa Rica S.C.R. Limitada, Synthes GmbH, Synthes Holding AG, Synthes Holding Limited, Synthes Inc., Synthes Medical Surgical Equipment & Instruments Trading LLC, Synthes Produktions GmbH, Synthes Proprietary Limited, Synthes S.M.P. S. de R.L. de C.V., Synthes Tuttlingen GmbH, Synthes USA LLC, Synthes USA Products LLC, TARIS Biomedical, TARIS Biomedical LLC, TearScience Inc., The Anspach Effort LLC, The Vision Care Institute LLC, Tibotec LLC, Torax Medical Inc., UAB "Johnson & Johnson", UAB Johnson & Johnson Eesti Filiaal (Estonian Branch), Vania Expansion, Verb Surgical, Verb Surgical Inc., Vision Care Finance Unlimited Company, Vogue International, Vogue International LLC, Vogue International Trading Inc., WH4110 Development Company L.L.C., XO1, XO1 Limited, Xian Janssen Pharmaceutical Ltd., Xian-Janssen Pharmaceutical Ltd. Beijing Branch Office, Xian-Janssen Pharmaceutical Ltd. Shanghai Branch Office, Zarbee's Inc., and Zarbee's Naturals.
Read More
How can I contact Johnson & Johnson?: Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The official website for the company is www.jnj.com. The company can be reached via phone at (732) 524-0400 or via fax at 732-214-0332.

This page (NYSE:JNJ) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial